Regulatory Approval

Karyopharm plans an accelerated FDA filing for its selinexor combo in myelofibrosis. The move hinges on a key surrogate endpoint and a race against competitors.

With federal-grade security clearance, Judi Health aims to replace the government's tangled legacy systems with a single platform for millions of beneficiaries.

Regeneron's Q2 results reveal soaring sales from Dupixent and EYLEA HD, a pivotal pipeline, and a major financial reset with Sanofi. What's next?

The UNESCO inscription of Dalian's Changshan Islands is more than a conservation win; it's a blueprint for integrating ecological assets with economic strategy.

With FDA clearance for IKS04, Iksuda Therapeutics unveils a novel co-dosing strategy to deliver a potent payload past notorious tumor barriers.

Kinross Gold unveils robust economics for its Chilean mega-project, balancing a massive valuation with a modern focus on sustainability and regional partnership.

A DHS anti-terrorism designation gives Titan HST a powerful liability shield, transforming the market for emergency tech and reshaping corporate risk management.

CFD broker Centrino Capital secures a Mauritius FSC license, a strategic move to anchor its global expansion and build trader trust in a tightening regulatory world.

A $3.5M fundraiser is just the start. Northwell's Feinstein Institutes are turning donations into FDA-approved nerve implants that are changing medicine.

An FDA panel's nod to controversial peptides seems to validate Hydreight's long-term strategy. But a closer look reveals a long road and a deep data gap.

Beyond strong Q2 earnings, ATCO is executing a masterclass in diversification, winning major contracts in modular construction, energy infrastructure, and Arctic defense.

Solid Q2 earnings are just the start. Photocure is moving beyond its core imaging tech with key acquisitions and AI partnerships, building a full-spectrum platform.

As Agilent prepares its Q3 report, the numbers are more than finance; they are a key signal for the future of diagnostics and life sciences innovation.

As Ceribell preps for a key investor conference, we analyze its AI-powered EEG platform, its rapid clinical adoption, and its strategy for market dominance.

Shionogi launches XOCOVA, the first oral pill to prevent COVID after exposure. With a 67% efficacy rate and a $1,400 price tag, who will it protect?

Pluri's subsidiary Cellav just won UK approval for its aesthetic product. But the real story is the science and a market potentially 4x larger than stated.

A landmark FDA approval allows Walter Reed to 3D-print cranial implants on-site, a strategic shift in military medicine powered by 3D Systems' expertise.

Two small firms just secured a patent until 2045 on a decades-old drug. It's a masterclass in strategy, revealing the future of pharmaceutical value.

Fairtility's expanded AI partnership with First Fertility isn't just a tech deployment. It's a key signal that the battle for dominance in the fertility market is shifting to a new trifecta: operational scale, data-driven precision, and a radically transparent patient experience.